11 Best Short Squeeze Stocks to Buy Now

Page 9 of 10

2. Verastem, Inc. (NASDAQ:VSTM)

Short Float: 37.03%

Verastem, Inc. (NASDAQ:VSTM) secures a spot in our list of 11 best short squeeze stocks to buy now. The company progresses with its Phase 3 ovarian cancer trial while AVMAPKI FAKZYNJA CO-PACK generates revenue.

Verastem, Inc. (NASDAQ:VSTM), operating from its headquarters in Massachusetts, is a development-stage biopharmaceutical company. Its focus is on discovering and commercializing novel cancer therapies, particularly those targeting cancer stem cells and RAS pathway–based malignancies.

On August 8, 2025, Verastem, Inc. (NASDAQ:VSTM) announced an update Phase 3 study in ovarian cancer. The company is engaged in a Phase 3 clinical trial, RAMP 301, to test a new combination therapy for recurrent low-grade serous ovarian cancer (LGSOC).

It announced that the study will focus on assessing the safety and effectiveness of the oral drugs avutometinib and defactinib against standard treatments. It’s an open-label, randomized trial, and participants can switch to the new drugs if their disease progresses. The study, which began in March 2024, is crucial for exploring new treatment options for this challenging cancer. It has the potential to impact on the competitive environment in oncology.

Additionally, in its earnings call, Verastem, Inc. (NASDAQ:VSTM) also highlighted securing FDA approval for its AVMAPKI FAKZYNJA CO-PACK nearly two months ahead of schedule. With this approval, the company enters the first-ever treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC). The product helped generate $2.1 million in net product revenue within just six weeks of its launch.

The company has a short float of 37.03%, suggesting elevated bearish bets that position the stock for significant gains if a bullish trigger were to materialize.

Page 9 of 10